$BCDA News

BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter

BioCardia Receives FDA Acceptance For Its Pre-Submission Package For Marketing Clearance Of Its Helix Catheter For Therapeutic And Diagnostic Agent Delivery

BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting

BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter

BioCardia Resubmits Pre-Submission To FDA For Its Q-Submission Program For Approval Of Its Helix Catheter For Therapeutic, Diagnostic Agent Delivery To The Heart

BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission

BioCardia Advancing Towards Shonin Pre-Market Regulatory Submission To Japan's Pharmaceutical And Medical Device Agency In Q4; Plans To File Follow-On De Novo Pre-Submission For Helix Transendocardial Delivery Catheter System

BioCardia Shares Fall 10% After Hours: Here's Why

BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference

BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval

BioCardia (BCDA) Q2 2026 Earnings Call Transcript

BioCardia Inc (BCDA) (Q2 2026) Earnings Call Highlights: Regulatory Wins in Japan and US ...

BioCardia, Inc. Q2 2026 Earnings Call Summary

BioCardia, Inc. (BCDA) Q2 2026 Earnings Call Transcript

BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results

BioCardia Q2 EPS $(0.13) Beats $(0.18) Estimate

BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026

BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities

BioCardia CEO Issued Shareholder Letter To Provide Update; Milestone Includes Submission For Japan's Pharmaceutical and Medical Device Agency Approval Planned For End Of 2026; Driving To Enroll Confirmatory CardiAMP HF II Trial In US

What's Going On With BioCardia Stock Tuesday?